Long-Term PEDF Release in Rat Iris and Retinal Epithelial Cells after Sleeping Beauty Transposon-Mediated Gene Delivery

Laura García-García,1,14 Sergio Recalde,1,14 Maria Hernandez,1,14 Jaione Beznartea,3 Juan Roberto Rodríguez-Madoz,2 Sandra Johnen,3 Sabine Diarra,3 Corinne Marie,4,5,6,7 Martina Kropp,10,11 Gabriele Thumann,10,11 Felipe Prosper,2,12 Patricia Fernandez-Robredo,1,15 and Alfredo Garcia-Layana1,13,15

Pigment epithelium derived factor (PEDF) is a potent antiangiogenic, neurotrophic, and neuroprotective molecule that is the endogenous inhibitor of vascular endothelial growth factor (VEGF) in the retina. An ex vivo gene therapy approach based on transgenic overexpression of PEDF in the eye is assumed to rebalance the angiogenic-antiangiogenic milieu of the retina, resulting in growth regression of choroidal blood vessels, the hallmark of neovascular age-related macular degeneration. Here, we show that rat pigment epithelial cells can be efficiently transfected with the PEDF-expressing non-viral hyperactive Sleeping Beauty transposon system delivered in a form free of antibiotic resistance marker miniplasmids. The engineered retinal and iris pigment epithelium cells secrete high (141 ± 13 and 222 ± 14 ng) PEDF levels in 72 hr in vitro. In vivo studies showed cell survival and insert expression during at least 4 months. Transplantation of the engineered cells to the subretinal space of a rat model of choroidal neovascularization reduces almost 50% of the development of new vessels.

INTRODUCTION

Elevated levels of vascular endothelial growth factor (VEGF) have been linked to the development of several ocular pathologies, including neovascular age-related macular degeneration (nAMD) and diabetic retinopathy.1 VEGF is a potent endothelial mitogen and vascular permeability factor and is considered the principal driver of choroidal neovascularization (CNV).2 The appropriate balance between the pro-angiogenic VEGF and the anti-angiogenic pigmented epithelium-derived factor (PEDF) in the retina could be essential to prevent the development of CNV.3 PEDF was first identified in retinal pigment epithelial (RPE) cells, but it is expressed in many cell types in the eye. In addition to a potent antiangiogenic effect, PEDF has neurotrophic and neuroprotective properties.4 The current treatment for neovascular retinal diseases is the inhibition of VEGF, specifically by the intravitreal injection of ranibizumab, the Fab fragment of a humanized antibody against VEGF (Lucentis, Novartis Pharma, Basel, Switzerland), aflibercept, a recombinant fusion protein (Eylea, Bayer Plc, UK), or bevacizumab, the whole humanized antibody against VEGF (Avastin, Roche, Basel, Switzerland). The injection of these anti-VEGFs controls CNV in nAMD patients, and in 30%–40% of cases, improves vision significantly.5–8 However, effective treatment requires frequent, costly9,10 and life-long intraocular injections, and can be associated with side effects, such as endophthalmitis, ocular hypertension, and retinal detachment.11,12 To avoid life-long, frequent intraocular injections, long-term delivery systems, e.g., nanoparticles,13 have been studied to transfer plasmids with the therapeutic gene. Likewise, many different antiangiogenic molecules are under study, such as sFLT01,14 Fh23K,15 or angiopoietin-1.16

Received 3 October 2016; accepted 7 August 2017; http://dx.doi.org/10.1016/j.omtn.2017.08.001.
1These authors contributed equally to this work.
2These authors contributed equally to this work.
Correspondence: Patricia Fernandez-Robredo, Experimental Ophthalmology Laboratory, University of Navarra, Navarra Institute for Health Research, IdiSNA, 31008 Pamplona, Spain.
E-mail: pfrobredo@unav.es
The delivery of anti-angiogenic factors to the retina using gene therapy could be approached by the direct administration of adenovirus (AAV) vectors; however, the required re-administration may compromise efficacy and might induce an immune response. Recent clinical studies showed that intravitreal sFLT0120 and subretinal endostatin/angiostatin21 injections seemed to be safe and well tolerated, although the efficacy in the CNV reduction was not confirmed. The Sleeping Beauty (SB) system that we proposed has a reduced immunogenicity,22 improved safety/toxicity profiles,23,24 and a relaxed limitation on the size of expression cassettes.25,26 We combined the non-viral hyperactive SB (SB100X) transposon system and the pFAR4 vector (free of antibiotic resistance genes) to deliver the PEDF gene to pigment epithelial cells. We transplanted the ex vivo engineered PEDF-expressing cells subretinally. Both the SB100X transposase and the PEDF gene are carried by pFAR4 derivatives. We hypothesized that we could provide efficient gene delivery, sustained gene expression, as well as improved biosafety by avoiding the potential transfer of antibiotic resistance genes into the host cell. The transposon-mediated integration of the PEDF gene into pigment epithelial cells would result in the continuous expression of the PEDF that would then inhibit the further development or even regression of CNV.24,27,28

Here, we report on the efficient transfection of rat RPE and iris pigment epithelial cells (IPEs) with the PEDF gene using the SB100X transposon system delivered by pFAR4 plasmids, the sustained release of recombinant PEDF in vitro, the proper localization of transfected cell transplanted subretinally, and the inhibition of neovascularization in a rat model of CNV.

RESULTS

PEDF Production by ARPE-19 and Rat Primary IPE and RPE Cells Transfected with the PEDF Gene

Before transfection with the SB transposon vector expressing PEDF, cells were characterized to confirm that they retained their expected phenotype in culture (Figure S1). ARPE-19 cells (Figures S1A–S1I) were positive for RPE65 and CRALBP, primary RPE cells (Figures S1J–S1O) were positive for RPE65 and Bestrophin, and IPE cells reacted positively for cytokeratin 18 (CK18) (Figures S1P–S1R). Quantification by ELISA detected continuous secretion of PEDF in the engineered ARPE-19, primary RPE, and IPE cells over a 72-hr period (Figures 1A and 1B). Importantly, PEDF secretion was increased from 24 to 72 hr in all three cell types (Figures 1A and 1B), reaching significance for IPE cells (p = 0.011). ARPE-19 cells secreted approximately 50-fold more PEDF than IPE or RPE primary cells did (10,434 ± 1,820 ng/mL secreted by ARPE-19 and 141 ± 13 ng/mL and 222 ± 14 ng/mL secreted by RPE and IPE cells, respectively). There was no detectable PEDF in control Venus-transfected samples.

PEDF secretion in vitro was maintained over 8 weeks for the three cell types studied (Figure 2) when transfected with PEDF and SB100X. A very significant change in PEDF levels was detected in IPE cells (p < 0.01). These results are in accordance with the ones obtained in previous studies.28

In addition to PEDF, a His-tagged version of PEDF (PEDF-His) was also transfected into ARPE-19, RPE, and IPE cells. Both forms of PEDF were easily detectable, as illustrated by western blots of culture supernatants of ARPE-19, RPE, and IPE cells (Figure 3).

Localization of Transplanted Venus-Transfected Cells in the Subretinal Space

Engineered Venus reporter-expressing cells were transplanted into the subretinal space of the rat. Cell localization of transplanted cells was assessed in flat mount retinas and cross-section cryosections of eyes 7 days after transplantation (Figures 4 and S2). Importantly, Venus-positive cells were located mostly around the site of injection (Figures 4A–4D). Flat mount images showed cells transplanted with Venus and labeled with CellBrite to confirm that the Venus-positive cells were the ones injected (Figures 4E–4L). In addition, flat mounts of the RPE/choroid complex observed by confocal microscopy showed that the Venus-transplanted cells were located close to the
tight junctions (labeled with ZO-1) of the native RPE, as illustrated in the orthogonal stack image (Figure S3).

Venus-transfected cells were stained with CellBrite and transplanted into the subretinal space. Immunostaining for RPE65 was done, but transplanted RPE cell staining was not clear, as described by Petrus-Reurer et al.29 (Figure 5). CellBrite marked organelles and the cytoplasmic membrane of cells, and it confirmed that Venus-positive cells were the transplanted cells, even if they were not positive for RPE65.

The correct location of transfected cells was also verified in eye samples transplanted with 1,000 IPE or RPE cells (Figure 6) transfected with Venus and previously stained with CellBrite. These samples showed the location of RPE (Figures 6A–6I) and IPE (Figures 6J–6W) cell clusters 1 week after transplantation.

PEDF-His production was tested 2 weeks after the transplantation. Confocal analysis of retinal flat mounts stained with antibodies to PEDF and 6-His peptide showed that the transplanted IPE cells were alive and produced PEDF-His in the subretinal space (Figure S4A). The orthogonal projections confirmed localization of the injected cells in the subretinal space (Figure S4B).

**Transfected Cells Survive Long-Term in the Subretinal Space**

Cell survival was evaluated in flat mounts of retinas from rats transplanted with Venus-transfected rat IPE and RPE primary cells. In the flat mounts, both RPE- and IPE-Venus-positive cells were detected at 7 days, 14 days, and 4 months after transplantation (Figure 7). In addition, a Z-orthogonal image showed the correct location in the subretinal space of the RPE-transplanted cells for 4 months (Figure S5).

**In Vivo Efficacy Study**

The effect of PEDF secretion was monitored 12 days after laser-CNV induction and 10 days post-subretinal transplantation of PEDF-expressing primary cells. The CNV area was stained with caveolin-1 antibody. It is evident from the photomicrographs (Figure 8A) and the area of CNV quantification (Figure 8B) that the area of CNV is 41% in the three rats transplanted with 10,000 PEDF-expressing IPE cells and 46% in the three rats transplanted with 20,000 PEDF-expressing RPE cells compared to the area of CNV in rats injected with saline. By contrast, no difference in the CNV lesion size was detected in the four control groups (Figure 8C).

**DISCUSSION**

We have previously reported the stable and efficient transgene integration in bovine, human, and immortalized rat RPE cells transfected with PEDF gene using the SB100X transposon system.28,30 Here, we show that ARPE-19 or rat primary RPE and IPE cells can be transfected by the PEDF expression construct using the SB100X transposase, both
encoded in pFAR miniplasmids. Cells secrete PEDF for at least 8 weeks into the culture media in vitro and 2 weeks transplanted subretinally. To our knowledge, this is the first demonstration that PEDF is expressed subretinally by PEDF-transfected primary cells for at least 2 weeks, and, as shown previously in similar studies, the transplanted cells reduce neovascularization in a rat model of CNV. Likewise, Venus-transfected rat IPE and RPE cells produced Venus fluorescent protein in the subretinal space for at least 4 months after transplantation.

Because the use on anti-VEGFs for the treatment of neovascular AMD is effective in only 30%–40% of patients and because it is necessary that anti-VEGFs be injected intraocularly every 4–8 weeks for the life of the patient and because the treatment is costly and may elicit significant side effects, it is imperative that novel, long-lasting, and more effective treatments be discovered. We have proposed the transplantation of PEDF-transfected pigment epithelial cells as a long-term alternative to the frequent intraocular injections of anti-VEGFs for the treatment for nAMD.

Given that gene delivery by viral vectors has significant limitations, we have investigated the use of the non-viral SB100X coupled with pFAR miniplasmid technology. The SB100X transposon vector provides efficient integration of the therapeutic gene into the host cell’s genome and sustained gene expression in many cell types, including RPE and IPE cells, as we report here. In addition, Sleeping Beauty is relatively safe because unlike integrating viral vectors, it...
does not target transcriptionally active genomic sequences. Furthermore, the use of pFAR4 plasmids would not transfer antibiotic resistance genes into the patient, and is thus safer than other plasmids. It eliminates the risk of colonization of endogenous flora, allergic reactions in susceptible patients to antibiotics, and the risk for horizontal gene transfer that could provide pathogenic bacteria with resistance to antibiotics that are used to treat humans. In our approach, ARPE-19 and primary IPE and RPE cells were transfected ex vivo, followed by transplantation into the subretinal space. The ex vivo strategy ensures that only the target cells are treated, which is a task that can be difficult using an in vivo delivery approach.

Here, we also report that the PEDF-expression RPE as well IPE cells transplanted into the subretinal space do not migrate to other layers of the retina and stay localized in the RPE layer. This is a critical issue for the treatment of nAMD because the secretion of PEDF must occur at the interface of the neural retina and Bruch’s membrane to prevent the choroidal vessels from penetrating through the Bruch’s membrane into the subretinal space.

In order to extend the therapeutic effect, plasmids encoding anti-angiogenic genes were delivered by nanoparticles and injected intravenously. However, the frequent injections of nanoparticles might lead to systemic toxicity, making this approach unlikely to become clinically relevant. The delivery of anti-angiogenic genes by viral vectors and even the transplantation of cells transfected ex vivo using viral vectors (AAV) followed by transplantation have been demonstrated. This approach has significant side effects, such as induced innate immune response. In addition, the high cost of vector production coupled with other safety concerns will preclude the use of viral vectors to become clinically widespread. In contrast to viral
gene delivery, the SB100X-mediated gene delivery is relatively safe, low cost, and provides a long-lasting therapeutic effect. We have previously shown that cells engineered by the SB100X system secrete PEDF in culture for at least 1 year. Similarly, in vivo studies have demonstrated that liver cells overexpressed the transgene for 7 months following SB100X-mediated delivery.

In summary, we have shown that SB100X-mediated delivery of the PEDF gene encoded in pFAR plasmids is efficient in vitro and in vivo, even when transfecting only 5,000–30,000 pigment epithelial rat cells. The transplanted cells survived for 4 months in rats and, furthermore, PEDF-expressing cells transplanted to the subretinal space secrete recombinant PEDF. We also observed an inhibition of the neovascularization in a rat model of CNV. The preclinical experiments presented here aim to bring the TargetAMD consortium to its goal to conduct a phase 1 clinical trial, in which IPE cells isolated from AMD patients will be treated ex vivo with the PEDF gene, followed by immediate autologous subretinal transplantation.

MATERIALS AND METHODS

Cell Culture

ARPE-19 cells (ATCC, Manassas, VA) were cultured in DMEM (Sigma, St. Louis, MO) supplemented with 10% fetal bovine serum (FBS; Gibco, Paisley, UK) and 1% penicillin/streptomycin/amphotericin B (Gibco), and maintained in a humidified atmosphere of 95% air and 5% CO2 at 37°C. The medium was changed three times a week, and cells were passaged at 70%–80% confluence at a ratio of 1:3.

Isolation and Culture of Rat Primary IPE and RPE Cells

The study was performed according to the Association for Research in Vision and Ophthalmology (ARVO) Resolution on the Use of Animals in Ophthalmic and Vision Research and approved by the Ethics Committee for Animal Research of the University of Navarra (protocol approval number 023-13).

Brown Norway rats (8–15 weeks) were used to isolate IPE and RPE cells. Eyes were cut below the ora serrata, and the anterior segment and posterior eyecup were separated. In the anterior segment, the iris was separated from the ciliary body and incubated in trypsin-EDTA (200 mg/L EDTA + 170,000 U Trypsin/L; Lonza, Walkersville, MD) at 37°C for 10 min. IPE cells were isolated by gently brushing the surface with a fire-polished glass spatula. Cells were centrifuged at 1,200 rpm for 10 min and the pellet was suspended in DMEM:F-12 (ATCC) medium supplemented with 10% FBS and 1% penicillin/streptomycin/amphotericin B (Lonza; complete medium) and plated into 24-well tissue culture plates. For RPE isolation, the neural retina was removed from the posterior eyecup and the RPE/choroid complex was maintained for 3 days in complete DMEM:F-12 medium; then, RPE cells were gently dislodged by brushing with a fire-polished glass spatula. The dislodged RPE cells were centrifuged and plated following the protocol used for IPE cells. IPE and RPE culture medium was changed twice a week.

To confirm the phenotype of primary cells, ARPE-19 and RPE cells were reacted with antibody to RPE65, CRALBP, and Bestrophin-1, and IPE cells were reacted with antibody to CK18. Briefly, cells were fixed in cold methanol overnight at −20°C, rinsed, permeabilized with 0.5% Triton X-100 (Sigma) containing 0.2% sodium azide (Sigma).
and 1% BSA (Sigma) for 30 min and incubated with primary antibodies: RPE65 (mouse monoclonal, ab78036, 1:100, Abcam, Cambridge, UK), Bestrophin-1 (rabbit polyclonal, orb323221, 1:250, Biorbyt, San Francisco, CA), CRALBP (rabbit polyclonal, orb182730, 1:250, Biorbyt), and CK18 (mouse monoclonal, M7010, 1:250, DAKO, Glostrup, Denmark). After overnight incubation with primary antibodies, cells were rinsed and incubated with the appropriate secondary antibody: Alexa Fluor Donkey anti-mouse, A10036, 1:250; (Invitrogen, Paisley, UK) and Alexa Fluor Donkey anti-rabbit, A21206, 1:250 (Invitrogen). DAPI (H1200, Vector) was used to label nuclei.

**Construction and Production of pFAR4 Derivatives**

To construct the pFAR4-ITRs CMV PEDF BGH and pFAR4-ITRs CMV PEDF-His BGH plasmids, relevant sequences (CMV-PEDF, CMV-PEDF-His, and BGH) were amplified by PCR using pT2-CMV-PEDF/EGFP as a template. This latter plasmid carries a human PEDF cDNA that was generated from ARPE-19 cells (ATCC). The PCR fragments were then inserted stepwise into pFAR4-ITRs, which is a pFAR4 derivative carrying the ITR sequences amplified from pT2/BH (a gift from Perry Hackett [Addgene plasmid # 26556, Addgene, Cambridge, MA]). pFAR4 is a miniplasmid vector that is devoid of antibiotic resistance genes. The expression cassette CMV-SB100x-SV40 was excised from pCMV (CAT) T7-SB100x and introduced into pFAR4, resulting in pFAR4-CMV-SB100X-SV40. Similarly, the DNA sequence encompassing CAGGS-Venus-SV40 flanked by both ITRs was excised from pT2-CAGGS-Venus and introduced into the pFAR4 vector, resulting in pFAR4-ITRs-CAGGS Venus.

All pFAR4 constructs were constructed and propagated using a dedicated bacterial strain (TM # 47-9a) that allows plasmid production in the absence of antibiotics. Plasmids were purified using Endofree plasmid preparation kits (Macherey Nagel, Hoerdt, France). Plasmid integrity and endotoxin levels were assessed using standard and LAL (Limulus Amoebocyte Lysate, Lonza) procedures, respectively.

**Transfection of ARPE-19 and Primary Cells**

All transfections were carried out by electroporation with the Neon Transfection System using the 10-μL kit (Invitrogen) following the manufacturer’s protocol. Briefly, 2,000–20,000 cells were suspended in 11 μL of buffer R and mixed with 2 μL of plasmid mixture (total DNA concentration of 500 ng) and electroporated. The ratio of plasmid to SB100x used was 1:16. Electroporation parameters for ARPE-19 cells were 1350 V, 20 ms, and 2 pulses, and electroporation parameters for primary RPE and IPE cells were 1,100 V, 20 ms, and 2 pulses.

![Figure 8. Effect of PEDF-Transfected Rat RPE and IPE Cells on Neovascularization in a Rat Model of Choroidal Neovascularization](image-url)

Photographs and measurement of CNV area of laser-induced CNV 10 days after treatment with an injection of 5 μL of saline, transplantation with 20,000 PEDF-transfected RPE cells, and 10,000 PEDF-transfected IPE cells. (A) Photographs of lesions. Each row represents 3 different CNV lesions from 3 different animals. Vessels were stained with Caveolin-1 (white). (B and C) Measurement of CNV area. The CNV area in rats transplanted with PEDF-transfected cells is approximately 50% less than that of the saline control (p < 0.05) (B). CNV area of control groups (C). There was no statistical difference among control groups. Area of CNV was calculated using Fiji software, and data were presented as a percentage of mean ± SEM (n = 3) versus the saline group. Scale bar, 50 μm. *p < 0.05.
Transfected cells were plated in 96-well plates. After electroporation, cells were cultured for 3 days in antibiotic-free DMEM:F-12 medium.

Quantification of PEDF by ELISA
To evaluate PEDF accumulation over 72 hr, 30,000 ARPE-19, primary rat RPE, and primary rat IPE cells transfected with pFAR4-CMV-PEDF or pFAR4-Venus were seeded in 96-well plates with a first change of medium after 3 days; PEDF accumulation was quantified during the following 3 days in the cell culture medium at 24, 48, and 72 hr. Phase contrast images were acquired before the cell cultures were terminated.

To determine PEDF secretion, 30,000 PEDF-transfected ARPE-19, primary rat RPE, and primary rat IPE cells were seeded in 96-well plates and PEDF secretion during 72 hr was quantified by ELISA at 3, 6, 9, 12, 15, 21, 28, and 56 days after transfection.

PEDF in culture medium was quantified by ELISA (DuoSet Human SerpinF1/PEDF Kit; R&D Systems, Abingdon, UK) according to the manufacturer’s protocol. Sample dilution for ARPE-19 cells was 1:5,000 and 1:100 for primary IPE and RPE cells.

PEDF Detection by Western Blot
PEDF protein expression and secretion was analyzed by western blot as previously reported.\(^\text{48,49}\) A volume of 7.5 \(\mu\)L was loaded on the gels, and loading was verified by Ponceau S red staining. To visualize PEDF, blots were reacted with monoclonal anti-PEDF antibody (PEDF [mouse monoclonal, MAB1059, 1:1,000, Chemicon], Temecula, CA) followed by horseradish peroxidase-conjugated goat anti-mouse antibody (sc2005; 1:10,000, Santa Cruz Biotechnology, Dallas, TX).

Localization of IPE and RPE Cells Transplanted Subretinally
Ten thousand primary IPE, RPE, or ARPE-19 cells were transplanted to the subretinal space of rats; for localization of the transplanted cells and evaluation of cell survival, rats were euthanized by cervical dislocation 7 days, 15 days, or 4 months after cell transplantation. Cells were transfected with pFAR4-Venus when the objective was cell localization and with pFAR4-CMV-PEDF-His to visualize PEDF production by immunofluorescence.

Eyes for histological staining or immunological analysis in tissue sections were fixed in 4% paraformaldehyde (PFA) for 1 hr, transferred into 30% sucrose for 24 hr prior to embedding in OCT compound (Tissue TeK, Sakura, Alphen aan den Rijn, Netherlands), and stored at \(-20^\circ\text{C}\) until use. Samples were sectioned in 12- to 14-\(\mu\)m sections with a cryostat (HM520 Microm) and collected on glass slices (Thermo, Braunshweig, Germany). Slides were stored at \(-20^\circ\text{C}\) until use. Slides stained with nuclear markers, DAPI (Vector) or TOPRO-3 (T3605, Life Technologies, Carlsbad, CA), were observed and photographed with a fluorescence (Axio Imager M1, Zeiss, Oberkochen, Germany) or confocal (LSM510 and LSM800; Zeiss) microscope.

Eyes to be analyzed in a flat mount were enucleated, and the choroid-RPE complex was fixed in 4% PFA for 1 hr at 4\(^{\circ}\text{C}\), rinsed with PBS, and flat mounted in a cross. Samples were then stained with TOPRO-3 or DAPI and visualized by confocal microscopy. For immunostaining, flat mounts were permeabilized with 0.25% Triton X-100 and 1% BSA for 30 min. Anti-PEDF (mouse monoclonal, MAB1059, 1:1,000, Chemicon), anti-Histidine (6-His, goat polyclonal, NBP1-25939, 1:400, Novus, Cambridge, UK), and zonula occludens with Alexa 594 (Z0-1, mouse monoclonal, 1364021A, 1:100, Invitrogen) antibodies were used for immuno-localization. After rinsing in PBS, flat mounts were incubated with the appropriate secondary antibodies (Alexa Fluor Donkey anti-mouse 488, A21202, 1:250 for PEDF and Alexa Fluor Donkey anti-Goat 594, A11058, 1:250 for 6-His) and counterstained with a nuclear marker (DAPI or TOPRO-3). A confocal microscope (LSM510 and LSM800 with Airyscan; confocal super-resolution imaging, Zeiss) was used to acquire immunofluorescence images and orthogonal projections over the z plane.

In order to be sure the injected and observed RPE and IPE cells were the transplanted cells, we stained the primary cells in culture with an infrared (647 nm) CellBrite dye (Cytoplasmic Membrane Labeling Kit, 1:200; Biotium, Hayward, CA), which labels cytoplasmic membranes and organelles. For the CellBrite staining, 1 mL was mixed in \(10^6\) RPE and IPE cells in DMEM:F12 supplemented with 10% FBS. The medium was removed, and the cells were rinsed with PBS and incubated for 40 min under cell culture conditions in the staining solution. Then, the cells were centrifuged three times at 1,200 rpm during 10 min and rinsed with PBS three times, and fresh medium was added before the injection procedure.

Laser-Induced CNV Model and Subretinal Cell Transplantation
Brown Norway male rats (8–10 weeks) were anesthetized, and eyes were dilated with a mixture of phenylephrine (7.8 mg/mL) and tropicamide (3 mg/mL) eye drops. Four laser photocoagulation spots (250-mW intensity, 0.05 s, and 75-\(\mu\)m spot size) were made concentrically around the optic nerve using a coverslip as a contact lens. Rupture of Bruch’s membrane was confirmed by bubble formation. Laser rupture sites with hemorrhage or subretinal bleeding at the time of laser application were excluded from analysis.\(^\text{50}\)

To evaluate the efficacy of the treatment, 2 days after inducing CNV, 10,000 IPE or 20,000 RPE cells transfected with pFAR4-CMV-PEDF-His were transplanted subretinally. For subretinal transplantation, rats were anesthetized by intraperitoneal administration of a mixture of ketamine (Imalgene 1000, Merial laboratories, Barcelona, Spain; 75 mg/kg) and xylazine (Xilagesic 2%, Calier laboratories, Barcelona, Spain; 10 mg/kg). For transplantation, pupils were dilated, eyes were anesthetized with a double anesthetic (Tetracaine chlorohydrate 1 mg/10 mL and oxibuprocarne chloride 4 mg/10 mL Alcon cusi, Barcelona, Spain) and stabilized using a suture, and the superior conjunctiva and subconjunctival tissue was cut to expose the sclera. A hole was made into the subretinal space using a 27G needle, and the appropriate number of cells suspended in 5 \(\mu\)L of PBS was infused using a 25-g De Juan cannula (Synergetics, O’Fallon, MO) attached to a 25-\(\mu\)L Hamilton syringe (Hamilton Meschntih, Höchst, Germany). The scleral wound was not sutured; oxytetracycline ointment...
Ten days after cell transplantation, rats were euthanized and the RPE/chorioid complex was processed for analysis in flat mount following the protocol described above for caveolin-1 immunostaining. The CNV area in retinal flat mounts was identified with caveolin-1 staining (Rabbit polyclonal, #3238, 1:400, Cell Signaling, Leiden, Netherlands), followed by reaction with secondary antibody Alexa Fluor Goat anti-Rabbit 488 (A11008, 1:250; Invitrogen). Flat mounts were photographed using a confocal microscope to obtain a single image. The CNV areas were quantified with Fiji software (a distribution of ImageJ) V1.48q by 2 investigators who were blinded to the study groups.

**Statistical Analysis**

Data are presented as mean ± SEM. Statistical analysis was performed using the SPSS 20 program (SPSS, Chicago, IL). In vitro studies were analyzed by using an ANOVA with repeated measures; a one-way ANOVA with Bonferroni and Dunnett post hoc tests was performed for the CNV area results after confirming the normal distribution of the data.

**SUPPLEMENTAL INFORMATION**

Supplemental Information includes five figures and can be found with this article online at http://dx.doi.org/10.1016/j.omtn.2017.08.001.

**VERSUS OF INTEREST**

Z. Izsvák and Z. Ivics are co-inventors on several patents on Sleeping Beauty transposon technology.

**ACKNOWLEDGMENTS**

This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement number 305134 (TargetAMD). L.G.-G. received a predoctoral grant from the Asociación de Amigos de la Universidad de Navarra. Perry Hackett (University of Minnesota) is kindly acknowledged for the gift of pT2/BH.

**REFERENCES**

1. Kwak, N., Okamoto, N., Wood, J.M., and Campochiaro, P.A. (2000). VEGF is major stimulator in model of choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 41, 3158–3164.
2. Sivaprasad, S., and Hykin, P. (2013). What is new in the management of wet age-related macular degeneration? Br. Med. Bull. 105, 201–211.
3. Bhutto, I.A., McLeod, D.S., Hasegawa, T., Kim, S.Y., Merges, C., Tong, P., and Lutty, G.A. (2006). Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration. Exp. Eye Res. 82, 99–110.
4. Tombran-Tink, J., and Barnstable, C.J. (2003). PEDF: a multifaceted neurotrophic factor. Nat. Rev. Neurosci. 4, 628–636.
5. Pieramici, D.J., and Avery, R.L. (2006). Ranibizumab: treatment in patients with neovascular age-related macular degeneration. Expert Opin. Biol. Ther. 6, 1237–1245.
6. Rosenfeld, P.J., Rich, R.M., and Lalwani, G.A. (2006). Ranibizumab: phase III clinical trial results. Ophthalmol. Clin. North Am. 19, 361–372.
7. Kovach, J.L., Schwartz, S.G., Flynn, H.W., Jr., and Scott, I.U. (2012). Anti-VEGF treatment strategies for wet AMD. J. Ophthalmol. 2012, 786870.
8. Kwong, T.Q., and Mohamed, M. (2014). Anti-vascular endothelial growth factor therapies in ophthalmology: current use, controversies and the future. Br. J. Clin. Pharmacol. 78, 699–706.
9. Duker, J.S., Wong, W.O., and Feuer, W.J. (2012). Retinal angiogenesis and neovascularization of the ocular fundus. Surv. Ophthalmol. 57, 481–508.
10. Jackson, T.L., and Kirkpatrick, L. (2011). Cost comparison of ranibizumab and bevacizumab. BMJ 343, d5058.
11. Haddick, L.J., Ramsey, D.J., and Young, L.H. (2014). Complications of subretinal photodynamic therapy: age-related macular degeneration. Semin. Ophthalmol. 29, 257–262.
12. Krishnan, R., Painter, A., and Loeb, J.L. (2009). Submacular haemorrhage after intravitreal bevacizumab compared with intravitreal ranibizumab in large occult choroidal neovascularization. Clin. Experiment. Ophthalmol. 37, 384–388.
13. Luo, L., Zhang, X., Hirano, Y., Tyagi, P., Barabas, P., Uehara, H., Miya, T.R., Singh, N., Archer, B., Qazi, Y., et al. (2013). Targeted intraretinal nanoparticle therapy reduces angiogenesis and fibrosis in primate and murine macular degeneration. ACS Nano 7, 3264–3275.
14. MacLachlan, T.K., Lukason, M., Collins, M., Munger, R., Ienberger, E., Rogers, C., Malatos, S., Dutfresne, E., Morris, J., Calcedo, R., et al. (2011). Preclinical safety
evaluation of AAV2-sFLT01 - a gene therapy for age-related macular degeneration. Mol. Ther. 19. 326–334.

15. Zhang, X., Das, S.K., Passi, S.F., Uehara, H., Bohnen, A., Chen, M., Tiern, M., Archer, B., and Ambati, B.K. (2015). AAV2 delivery of Flk23k intracaptors inhibits marine choroidal neovascularization. Mol. Ther. 23. 226–234.

16. Lambert, N.G., Zhang, X., Rai, R.R., Uehara, H., Choi, S., Carroll, L.S., Das, S.K., Caboon, J.M., Kirk, B.H., Bentley, B.M., et al. (2016). Subretinal AAV2-COMP-Angl suppresses choroidal neovascularization and vascular endothelial growth factor in a murine model of age-related macular degeneration. Exp. Eye Res. 145. 248–257.

17. Campochiaro, P.A., Lauer, A.K., Sohn, E.H., Mir, T.A., Naylor, S., Anderton, M.C., Walisko, O., Schorn, A., Rolfs, F., Devaraj, A., Miskey, C., Izsvák, Z., and Ivics, Z. (2004). Development of hyperactive Sleeping Beauty transposition into cellular therapies: victories and challenges. BioEssays 32. 756–767.

18. Liu, G., Geurs, A.M., Yae, K., Srinivasan, A.R., Fahrenkrug, S.C., Largerdaeda, D.A., Takeda, J., Horie, K., Olson, W.K., and Hackett, P.B. (2005). Target-site preferences of Sleeping Beauty transposons. J. Mol. Biol. 346. 161–173.

19. Yant, S.R., Wu, X., Huang, Y., Garrison, B., Burgess, S.M., and Kay, M.A. (2005). High-resolution genome-wide mapping of transposon integration in mammals. Mol. Cell. Biol. 25. 2085–2094.

20. Marie, C., Vandemeuleen, G., Quiviger, M., Richard, M., Prat, V., and Schermer, D. (2010). pFARs, plasmids free of antibiotic resistance markers, display high-level transgene expression in muscle, skin and tumour cells. J. Gene Med. 12. 332–333.

21. Askou, A.L., Aagaard, L., Kostic, C., Arsenijevic, Y., Høllens, A.K., Bek, T., Jensen, T.G., Mikkelsen, J.G., and Corydon, T.J. (2015). Multigencodeviral vectors for combi ned and tissue-specific expression of mRNA- and protein-based antiangiogenic factors. Mol. Ther. Methods Clin. Dev. 2. 14064.

22. Hartman, Z.C., Appledorn, D.M., and Amaltiano, A. (2008). Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res. 132. 1–14.

23. Yoshioa, Y., Abe, T., Wakisuwara, R., Moriyia, T., Mochizukia, S., Saigo, Y., Saito, T., Murata, H., Tokitaa, Y., Iseyaa, T., et al. (2006). Recombinant AAV transduced iris pigment epithelial cell transplantation may transfer vector to native RPE but suppress systemic dissemination. Invest. Ophthalmol. Vis. Sci. 47. 754–752.

24. Xue, X., Huang, X., Nodland, S.E., Matéss, L., Ma, L., Izsvák, Z., Ivics, Z., LeBien, T.W., McVor, R.S., Wagner, J.E., et al. (2009). Stable gene transfer and expression in cord blood-derived CD34+ hematopoietic stem and progenitor cells by a hyperactive Sleeping Beauty transposon system. Blood 114. 1319–1330.

25. Hackett, P.B., Largerdaeda, D.A., and Cooper, L.J. (2010). A transposon and transposase system for human application. Mol. Ther. 18. 674–683.

26. Chung, S.I., Moon, H., Kim, D.Y., Cho, K.J., Ju, H.L., Kim, D.Y., Ahn, S.H., Han, K.H., and Ro, S.W. (2016). Development of a transgenic mouse model of hepatocellular carcinoma with a liver fibrosis background. BMC Gastroenterol. 16. 13.

27. Turnen, T.A., Kurikupuro, J., Heikura, T., Vuorio, T., Hyytönen, E., Izsvák, Z., and Ylä-Herttuala, S. (2016). Sleeping Beauty transposon vectors in liver-directed gene delivery of LDLR and VLDLR for gene therapy of familial hypercholesterolemia. Mol. Ther. 24. 620–635.

28. Matés, L., Chua, M.K., Belay, E., Jerchow, B., Manjo, N., Acosta-Sanchez, A., Grezda, D.P., Schmitt, A., Becker, K., Matras, I., et al. (2009). Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat. Genet. 41. 753–761.

29. Fernandez-Robredo, P., Recalde, S., Moreno-Orduña, M., Garcia-Garcia, L., Zarrant-Ventura, J., and Garcia-Layana, A. (2013). Azithromycin reduces inflammation in a rat model of acute conjunctivitis. Mol. Vis. 19. 153–165.

30. Ivanescu, A.A., Fernandez-Robredo, P., Heras-Mulero, H., Sádaba-Echarri, L.M., Garcia-Garcia, L., Fernandez-Garcia, V., Moreno-Orduña, M., Redondo-Exposito, A., Recalde, S., and Garcia-Layana, A. (2015). Modifying choroidal neovascularization development with a nutritional supplement in mice. Nutrients 7. 5423–5442.

31. Garcia-Layana, A., Vásquez, G., Salinas-Alamán, A., Moreno-Montañés, J., Recalde, S., and Fernández-Robredo, P. (2009). Development of laser-induced choroidal neovascularization in rats after retinal damage by sodium iodate injection. Ophthalmic Res. 42. 205–212.